Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 120, Issue 12, Pages 4179-4182Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI45406
Keywords
-
Categories
Funding
- NCI NIH HHS [R01-CA131188, R01 CA131188] Funding Source: Medline
Ask authors/readers for more resources
The retinoblastoma tumor suppressor gene (RB1; encoding RB) is often cited as a gatekeeper, whose inactivation - direct or indirect - is a rate-limiting step for tumor initiation. However, in this issue of the JCI, Sharma et al. show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease. This role for RB1 was linked to both E2F transcription factor 1-driven upregulation of the androgen receptor (AR) and increased recruitment of the AR to target gene promoters. This unexpected function for RB1 in late-stage cancer calls upon us to reassess the significance of RB1 inactivation in other cancers in terms of its timing, function in disease etiology, and relevance for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available